Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034)
LAS VEGAS, July 10, 2025 /PRNewswire/ — Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain. This buildup leads to cognitive impairments, visual hallucinations, Parkinson-like motor symptoms, and fluctuating attention levels.
LBD encompasses two main subtypes: Dementia with Lewy bodies (DLB), where cognitive issues arise before or at the same time as motor symptoms, and Parkinson's Disease Dementia (PDD), in which dementia appears more than a year after the onset of motor symptoms. While both share the same underlying pathology involving alpha-synuclein, they differ based on the sequence of symptom development.
Diagnosis is primarily clinical, supported by cognitive assessments, neuroimaging, and sleep evaluations, although definitive diagnosis is possible only post-mortem. Treatment is symptom-oriented and includes cholinesterase inhibitors, selective use of Parkinson's medications, and interventions for psychiatric and sleep disturbances, though care must be taken not to worsen cognitive issues.
According to DelveInsight, there were around 12 million diagnosed cases of dementia across the 7MM in 2024, with expectations of significant growth through 2034, driven by a rising CAGR. According to DelveInsight's 2024 analysis, approximately 330K diagnosed prevalent cases of DLB were reported in the US, emphasizing the significant disease burden in one of the world's key pharmaceutical markets. This substantial patient population underlines the urgent need for improved diagnostic tools and effective treatment options within the US healthcare landscape.
Download the report to understand which factors are driving Lewy body dementia epidemiology trends @ Lewy Body Dementia Treatment Algorithm
Currently, LBD has no approved disease-modifying therapies (DMTs), and existing treatments offer only partial symptomatic relief. These are often limited by side effects or may worsen certain symptoms. The complexity of managing overlapping cognitive, motor, and psychiatric issues underscores the urgent need for more effective, targeted, and better-tolerated therapies to improve quality of life for patients.
Lewy body dementia presents with a distinctive mix of cognitive, motor, and psychiatric symptoms. Existing treatments tend to address these symptoms individually and often fall short in effectiveness. There is a pressing need for therapies that target multiple symptoms simultaneously or are customized to LBD's underlying neurobiology, offering more comprehensive and lasting care.
Patients with LBD are particularly vulnerable to adverse drug reactions, especially from antipsychotics, which can cause severe, even life-threatening side effects. This drug sensitivity severely limits treatment options and adds complexity to clinical management. Safer, more tolerable therapies that alleviate neuropsychiatric symptoms without worsening cognition or motor function are critically needed.
Currently, there are no dependable, non-invasive biomarkers to confirm an LBD diagnosis during life. Diagnosis relies mainly on clinical presentation, which often results in misdiagnosis or delayed recognition. A validated biomarker would enhance early and accurate diagnosis, aid in identifying appropriate patient groups, and facilitate clinical trial participation, advancing the development of targeted treatments.
Learn more about the Lewy body dementia treatment @ New Treatment for Lewy Body Dementia
As the current Lewy body dementia market is marked by a notable lack of approved treatment options, it presents a significant opportunity for the introduction of new therapies. This shortfall highlights the urgent need for innovative drugs that can address the disease's intricate pathology. With limited competition and a strong unmet medical need, companies developing treatments in this area may find a favorable environment.
The LBD drug development pipeline remains relatively sparse, with only a handful of pharmaceutical companies actively working on targeted therapies. Although the demand for effective treatments is increasing, innovation is still in its early stages. Promising investigational candidates such as Neflamapimod, Zervimesine, and Nilotinib have shown potential in addressing the multifaceted symptoms of LBD, indicating early progress toward bridging the significant therapeutic gap.
Discover which therapies are expected to grab major Lewy body dementia market share @ Lewy Body Dementia Market Report
Neflamapimod, an investigational central nervous system (CNS) therapy developed by CervoMed and originally licensed from Vertex Pharmaceuticals, has been granted Fast Track designation (FTD) by the FDA for the treatment of dementia with Lewy bodies (DLB). The drug has exhibited a strong safety profile in over 350 patients and promising efficacy in Phase II studies. CervoMed holds multiple patents for its use and formulation, protecting 2039. Initial proof-of-concept data was released in Q1 2025, with additional results expected in the second half of 2025. A Phase III trial is anticipated in mid-2026, contingent on regulatory feedback and funding.
In June 2025, CervoMed announced a strategic hire to bolster the development and commercialization of neflamapimod, along with efforts to reinforce Chemistry, Manufacturing, and Controls (CMC) leadership in preparation for scaling up production.
Zervimesine (CT1812) is under investigation for mild-to-moderate DLB. The Phase IIa SHIMMER trial (COG1201) it demonstrated a favorable safety profile and consistent efficacy signals across behavioral, cognitive, functional, and motor areas, with benefits increasing over six months. These results support its continued development.
Nilotinib, originally approved by Novartis for a different indication, is being repurposed for Parkinson's disease dementia (PDD). Acting as a c-ABL and DDR-1 inhibitor, it is currently in Phase II trials aiming to enhance protein clearance and mitigate neurodegeneration. Preliminary findings suggest improvements in both cognition and motor skills. KeifeRx is collaborating on Nilotinib's clinical assessment and sees promise in its potential as a disease-modifying therapy for neurodegenerative diseases. KeifeRx is also advancing KFRX05, another candidate for PDD, currently in the IND-enabling stage.
Discover more about drugs for Lewy body dementia in development @ Lewy Body Dementia Clinical Trials
The anticipated launch of these emerging therapies for Lewy body dementia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Lewy body dementia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the market size for Lewy body dementia is expected to grow at a significant CAGR by 2034. This growth is mainly driven by increased awareness, improved diagnostic capabilities, and an aging global population. The lack of disease-modifying therapies has created a strong demand for novel treatment options. Ongoing clinical trials targeting alpha-synuclein pathology are attracting significant investment. Additionally, regulatory support is accelerating therapeutic development in this underserved neurodegenerative space.
DelveInsight's latest published market report, titled as Lewy Body Dementia Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the Lewy body dementia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The Lewy body dementia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Total Diagnosed Prevalent Cases of Dementia
Total Diagnosed Prevalent Cases of LBD
Gender-specific Diagnosed Prevalent Cases of LBD
Type-specific Diagnosed Prevalent Cases of LBD
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Lewy body dementia market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based Market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
Industry Expert's Opinion
Access and Reimbursement
Download this Lewy body dementia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the Lewy body dementia market. Also, stay abreast of the mitigating factors to improve your market position in the Lewy body dementia therapeutic space.
Related Reports
Lewy Body Dementia Pipeline
Lewy Body Dementia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key FCS companies, including EIP Pharma Inc., Cognition Therapeutics, Eisai Inc., Sun Pharma Advanced Research Company Limited, Georgetown University, Eli Lilly and Company, CuraSen Therapeutics, Inc., Athira Pharma, Aptinyx Inc., among others.
Dementia Market
Dementia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies including Eisai Co., Ltd., Eli Lilly and Company, Novartis AG, DAIICHI SANKYO COMPANY, LIMITED, AbbVie Inc., Lundbeck, Biogen, Cipla, among others.
Alzheimer's Disease Market
Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol-Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC, among others.
Parkinson's Disease Market
Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/comprehensive-lewy-body-dementia-market-analysis-of-evolving-trends-and-anticipated-growth-trajectory-during-the-forecast-period-20252034–delveinsight-302502058.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
36 minutes ago
- Malaysian Reserve
ALMA LAUNCHES THE WORLD'S FIRST AI-ASSISTED, PROVIDER-APPROVED MEDICAL-GRADE SKINCARE SYSTEM WITH NEARLY 12 MILLION UNIQUE FORMULATIONS
CHICAGO, July 23, 2025 /PRNewswire/ — Alma, a global leader in aesthetic solutions, proudly presents Universkin by Alma, a groundbreaking, medical-grade skincare line designed to meet the dynamic needs of today's patients and the physicians who care for them. Moving beyond the one-size-fits-all skincare model, Universkin by Alma is setting a new benchmark in personalized treatment with the world's first AI-assisted medical skincare line, offering providers a smarter approach to recommending the use of 18 essential BioActives. At the core of Universkin by Alma is AI-assisted analysis software designed to streamline clinical decision-making. In under a minute, providers can capture a facial image, perform intelligent skin analysis, and generate a personalized formulation for approval—selected from 487,678 combinations and nearly 12 million unique outcomes—precisely tailored to each patient's skin profile and concerns. "Universkin by Alma brings medical-grade personalization to the forefront of patient care," said Lior Dayan, CEO of Alma. "By integrating advanced, science-backed ingredients with a personalized, smarter approach, we're empowering physicians to extend the impact of aesthetic care beyond the clinic and into every patient's daily routine. As the first AI-assisted system of its kind, Universkin by Alma also lays the foundation for a broader intelligent infrastructure, one designed to optimize the patient experience, elevate clinical outcomes, and transform aesthetic care into a personalized, continuous journey." "Personalization is the future of aesthetic medicine. Every patient's skin is unique, and tailored treatments allow us to address their specific needs for the best possible results," said Lawrence Iteld, MD, a board-certified plastic surgeon at Iteld Plastic Surgery in Chicago, IL. "With Universkin by Alma, I offer more than just skincare—we deliver real, lasting skin health, customized to each patient's unique skin journey." The Universkin by Alma system is structured around four key pillars: Cleanse, Treat, Strengthen, and Soothe, each supported by innovative product formulations featuring Complex P or patented P-HC technology: Cleanse: Hydrating Oil Cleanser with patented P-HC technology, gently removes makeup and impurities while nourishing the skin. Treat: The Activating Serums, powered by patented P-HC technology, are at the heart of the AI-assisted personalization process—enabling providers to generate nearly 12 million unique recommendations that address eight key skin concerns: oxidative stress, texture, redness, hydration, exfoliation, oily skin, pigmentation, and impurities. Strengthen: HA Boosting Serum with Complex P technology deeply hydrates and strengthens the skin's structure. Complementing it are Barrier Nourishing Crèmes (in Light and Rich textures) with P-HC technology; these products nourish the skin barrier, tailored to suit different skin types. Soothe: The Barrier Restoring Balm with P-HC technology calms the appearance of redness, minimizing sensitivity, and reinforcing the skin barrier, especially after aesthetic treatments. With Universkin, Alma introduces a more innovative, personalized approach to medical-grade skincare—one that delivers both efficiency and efficacy. "At our practice, we believe in inclusive, individualized care—there's no one-size-fits-all," said John Burns, MD, board-certified plastic surgeon and medical director at JOLA in Dallas, TX. "With nearly 12 million combinations of AI-assisted recommendations, Universkin by Alma allows us to tailor skincare while streamlining routines for both staff and patients." "Universkin by Alma reflects our core value of innovation through care, offering a treatment experience that delivers personalized results," said Keith Adams, the President of Alma North America. "We're committed to ensuring our customers remain at the forefront of aesthetic medicine with solutions that cater to each patient's unique needs." For more information about Universkin by Alma or to find a provider near you, visit About Alma Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of- the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Colorado workers urged to 'Know Their Flow' as Pinnacol launches 'The Great Hydr8' campaign to combat silent summer danger
Workers in Colorado are 39% more likely to experience heat-related illness from 10 a.m. to noon DENVER, July 23, 2025 /PRNewswire/ — As Colorado heads into the warmer months, bringing an increase in outdoor work and recreational activities, Pinnacol Assurance, the state's largest workers' comp carrier, is launching 'The Great Hydr8' campaign to remind workers about the dangers of dehydration and provide actionable steps to stay safe in the heat, including proactively monitoring their hydration levels using a simple yet vital indicator: the color of their urine. This campaign features an eight-level urine color chart, and uses eight heat safety and hydration tips to educate workers and the greater community about the often-underestimated risks of dehydration by providing actionable guidance to stay safer in the heat. Claims data reveals heat-related illness trends According to a new analysis of Pinnacol claims, during the months of May to August, workers are 39% more likely to experience heat-related illness. Incidents leading to claims are 95% more likely between 10 a.m. and noon, spiking at noon. Due to the nature of their work, the following industries and professions face a heightened risk of dehydration: Police officers: Often exposed to the elements for extended periods during patrols, traffic control, and incident response, leading to increased fluid loss Outdoor recreation and tourism staff: Guides, instructors and park employees working in the elements Education professionals: Those working outdoors or in non-air-conditioned facilities during summer months Firefighters: Subject to extreme heat and heavy physical exertion while wearing protective gear, resulting in rapid dehydration Restaurant/fast food staff: Often working in hot environments and with high physical demands 'Staying properly hydrated is not just about quenching thirst; it's a fundamental aspect of workplace safety, especially here in Colorado,' says Monica Cabrera, Pinnacol's learning safety specialist. 'The state's high elevation means thinner air, which can lead to faster dehydration. The intense Colorado sun results in high ultraviolet radiation levels, further stressing the body and increasing the risk of heat-related injuries and illnesses.' The Great Hydr8: Your body's hydration indicator in 8 shades Pinnacol's 'The Great Hydr8' campaign emphasizes the importance of using urine color as a quick and easy indicator of hydration levels. Pale straw yellow: This is the ideal color and indicates you are likely well hydrated. Keep up your current fluid intake to maintain this healthy level. Light yellow: This is generally acceptable, but be mindful of your activity level and the heat. Increase your fluid intake slightly, especially if you are working intensely or in direct sunlight. Dark yellow / amber: This is a warning sign that you are likely dehydrated and need to take immediate action. Stop what you are doing, find a cool place, and drink plenty of water or electrolyte-rich beverages. Continue to monitor your urine color. Honey / dark brown: This indicates severe dehydration and requires immediate attention. Seek medical help if you experience other symptoms, such as dizziness, confusion, decreased urination or rapid heartbeat. Actionable guidance for staying safe in the heat Pinnacol urges all workers, especially those in high-risk industries, to follow these proactive steps to stay hydrated and prevent heat-related illnesses: Hydrate early and often: Don't wait until you feel thirsty to drink. Sip water or electrolyte-rich drinks throughout the day. Aim for regular intake, especially before, during and after physical exertion. Note that excessive water intake can be dangerous — drink water consistently, but avoid consuming extremely large amounts in a short period. Carry water with you: Make sure you have access to water at all times, especially on job sites or during outdoor activities. Take regular breaks: Schedule short breaks in shaded areas or air-conditioned spaces to allow your body to cool down and rehydrate. Wear appropriate clothing: Opt for light-colored, loose-fitting and breathable clothing to help your body regulate its temperature. Wear a hat and sunglasses for added protection from the sun. Be aware of peak heat times: Take extra precautions during the hottest parts of the day (typically mid-morning to mid-afternoon). If possible, schedule strenuous tasks for cooler times. Understand the risks of altitude and UV: Be extra diligent about hydration at higher elevations and always use sunscreen with a high SPF to protect your skin from intense UV radiation, which can exacerbate heat stress. Know the signs of heat illness: Be aware of the symptoms of heat exhaustion (heavy sweating, weakness, dizziness, nausea, headache) and heatstroke (high body temperature, confusion, seizures, loss of consciousness), and know what to do if someone experiences them. Seek immediate medical attention for heatstroke. Listen to your body: Pay attention to how you are feeling and don't push yourself too hard in the heat. If you feel unwell, stop working and seek help. Pinnacol encourages employers and employees to share this important information so all Coloradans can prioritize hydration. About Pinnacol Pinnacol Assurance is a top-performing provider of workers' compensation insurance. We offer top-rated injured worker care, customized safety solutions, and a comprehensive return-to-work program that helps our members reduce risk and save costs. You can see our investment in the community through our nationally recognized apprenticeship program and Pinnacol Foundation scholarship program. Pinnacol's team members, culture of caring and top-rated services have received numerous awards, affirming our commitment to the people and communities we serve. Learn more at Contact: Liz Johnson Director, Public Relations 720.939.7238 (mobile)[email protected]
Malaysian Reserve
21 hours ago
- Malaysian Reserve
United Breast Cancer Foundation Expands Support in the Southeast with Major Mattress & Pink Bag Event in Tallahassee, FL
130 Breast Cancer Patients and Survivors Served During Five-Day Distribution of Donated Essentials TALLAHASSEE, Fla., July 22, 2025 /PRNewswire/ — United Breast Cancer Foundation (UBCF) hosted a multi-day Mattress & Pink Bag Event at Governor's Square Mall in Tallahassee, FL, from June 26th through the 30th. The impactful event provided essential support to 130 breast cancer patients and survivors, distributing more than $1.45 million in donated goods including therapeutic mattresses, clothing, shoes, personal care products, household items, toys, and children's items and more. Attendees came from Florida and many surrounding states, with some coming from as far as Ohio, Texas, Pennsylvania and Maine —underscoring the event's wide-reaching impact. This event marked UBCF's first time offering the Mattress & Pink Bag Program in a multi-day format. The expanded schedule increased accessibility, reduced wait times, and allowed for deeper engagement with participants. The days were filled with gratitude, hugs, tears, and connection—a meaningful experience for recipients, volunteers, and staff alike. Event attendee, Alisa wrote in to share her gratitude, 'Dear UBCF Team, I wanted to personally thank you for the generous gifts I received at the Florida Mattress & Pink Bag Shopping Event. I didn't want to miss the chance to reach out and express how much it truly means to me to go to sleep more comfortably at night without the aches and pains I experienced before getting my new mattress. The event was not only a beautiful experience, but also a powerful reminder that kindness and support still exist in 'abundance'. Receiving the gifts made me feel seen, supported, and genuinely cared for and I am so grateful for everything I received. Thank you again for all that you do for breast cancer patients and survivors. Your work makes a real difference, and I'm incredibly thankful to be one of the people impacted by your love and compassion. With heartfelt appreciation, Alisa' Kara shared this beautiful message, 'I wanted to be sure I reached out to say thank you a million times for the amazing experience you brought to Tallahassee. The mattress is the best mattress I have ever had in my life, and that dern pillow we got to pick out is insane. I have never loved a pillow so much lol. Everything was amazing especially the experience of being around others in a similar situation as myself. Thank you again and many blessings.' High-quality sleep is critical for breast cancer recovery. A 2025 study published in BMC Cancer reported that sleep disturbances are among the strongest predictors of reduced quality of life in breast cancer patients undergoing chemotherapy. Additionally, the American Academy of Sleep Medicine found that better sleep efficiency was linked to significantly longer survival times—women with advanced breast cancer who slept well lived twice as long on average. Community support also plays a powerful role in survivorship. Research has shown that patients who feel supported and heard experience lower levels of depression, pain, and inflammation and improved long-term quality of life. Events like this are especially important in states like Florida, where breast cancer is a serious public health concern. It is the most commonly diagnosed cancer among women in Florida, with over 19,000 new cases diagnosed each year. Florida also faces persistent disparities in late-stage diagnoses—particularly in underserved communities. A statewide analysis found that patients from high-poverty rural areas had 31% higher odds of being diagnosed at a late stage compared to patients from low-poverty urban areas. Patients in high-poverty areas often face barriers such as limited access to healthcare, financial challenges, lower awareness of breast cancer symptoms, and systemic healthcare inequities—all of which contribute to delays in screening and diagnosis. This makes outreach and support events like UBCF's Mattress & Pink Bag Event vital to helping bridge these gaps. UBCF extends its sincere gratitude to the community partners who made this event possible. Special thanks to Governor's Square Mall for generously donating the event space, Whole Foods Market for providing dedicated volunteers who brought compassion, and People Ready for supplying reliable staffing support throughout the multi-day event. Their contributions were essential to the event's success and the meaningful experiences shared by all who attended. UBCF's next Mattress & Pink Bag Event will take place in Jonesboro, Arkansas, from October 16–19, 2025. As always, the event is free to qualified breast cancer patients and survivors. To learn more about UBCF's programs, to apply for assistance, or to make a donation, visit About UBCF United Breast Cancer Foundation is a non-profit founded in 2000 with a mission to make a positive difference in the lives of those impacted by breast cancer. UBCF is committed to gifting helpful and supportive donated items, providing financial grants to those in need, and funding breast health and wellness services focused on education, screening, treatment, recovery, overall wellness, and beyond. The platinum rated, 4-star charity offers numerous life-supporting patient and family programs available to women, men, and families nationwide. Tax-deductible contributions (consult your tax advisor) may be made towards UBCF's programs. UBCF accepts contributions through Donor Advised Funds and vehicle and property donations as well.
